Breaking News

Intas Pharmaceuticals Launches Biosimilar INTACEPT

Launch of first etanercept biosimilar reduces the cost of treatment down to 50 percent

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Intas Pharmaceuticals have launched INTACEPT, the first biosimilar to Amgen’s Enbrel (etanercept). INTACEPT, Intas’ etanercept, has been launched in two strengths, 25 mg in 0.5 ml and 50 mg in 1.0 ml preservative free solution, in easy to use pre-filled syringes. INTACEPT is the first etanercept biosimilar manufactured in India and is indicated for rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis and plaque psoriasis, all debilitating autoimmune di...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters